Cargando…

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign

BACKGROUND: From 2019 to 2021, Rwandan residents of the border with the Democratic Republic of the Congo were offered the Ad26.ZEBOV (adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein) and MVA-BN-Filo (modified vaccinia virus Ankara vector vaccine, encoding glycoproteins from Ebola...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyombayire, Julien, Ingabire, Rosine, Magod, Ben, Mazzei, Amelia, Mazarati, Jean-Baptiste, Noben, Jozef, Katwere, Michael, Parker, Rachel, Nsanzimana, Sabin, Wall, Kristin M, Sayinzoga, Felix, Tichacek, Amanda, Robinson, Cynthia, Hammoud, Niina, Priddy, Frances, Allen, Susan, Karita, Etienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833427/ https://www.ncbi.nlm.nih.gov/pubmed/35776140 http://dx.doi.org/10.1093/infdis/jiac283

Ejemplares similares

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial
por: Karita, Etienne, et al.
Publicado: (2022)

Leapfrogging with technology: introduction of a monitoring platform to support a large-scale Ebola vaccination program in Rwanda
por: Mc Kenna, Paula, et al.
Publicado: (2021)

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children( )
por: Ishola, D
Publicado: (2022)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Alexandre, Marie, et al.
Publicado: (2023)

Best practices and lessons learned from implementing a massive Ebola vaccination program: Summarizing UMURINZI team experience
por: Dine, Roseline Dzekem, et al.
Publicado: (2023)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022)

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
por: Manno, Daniela, et al.
Publicado: (2023)

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2020)

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
por: Afolabi, Muhammed O, et al.
Publicado: (2022)

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
por: Anywaine, Zacchaeus, et al.
Publicado: (2019)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
por: Mutua, Gaudensia, et al.
Publicado: (2019)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Barry, Houreratou, et al.
Publicado: (2021)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021)

Cross-sectional assessment of government health center needs to implement long-acting reversible contraception services in rural Rwanda
por: Mazzei, Amelia, et al.
Publicado: (2021)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
por: Legardy-Williams, Jennifer K., et al.
Publicado: (2020)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
por: Gsell, Pierre-Stéphane, et al.
Publicado: (2017)

1049. Minimal Transient HIV-1 Viremia Following Vaccination Regimens Containing AD26. ZEBOV and MVA-BN-Filo in ART-Suppressed People Living with HIV
por: Custer, Benjamin L, et al.
Publicado: (2021)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
por: Ishola, David, et al.
Publicado: (2022)

Community health worker promotions increase uptake of long-acting reversible contraception in Rwanda
por: Mazzei, Amelia, et al.
Publicado: (2019)

Sexual behavior among volunteers enrolled in a Phase I HIV vaccine trial: experience of Projet San Francisco in Kigali, Rwanda
por: Mukamuyango, J, et al.
Publicado: (2012)

Etiologies of genital inflammation and ulceration in symptomatic Rwandan men and women responding to radio promotions of free screening and treatment services
por: Wall, Kristin M., et al.
Publicado: (2021)

Developing and validating a risk algorithm to diagnose Neisseria gonorrhoeae and Chlamydia trachomatis in symptomatic Rwandan women
por: Wall, Kristin M., et al.
Publicado: (2021)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

Implementation and evaluation of a large-scale postpartum family planning program in Rwanda: study protocol for a clinic-randomized controlled trial
por: Wall, Kristin M., et al.
Publicado: (2022)

A mixed-methods study of factors influencing postpartum intrauterine device uptake after family planning counseling among women in Kigali, Rwanda
por: Tounkara, Mariama S., et al.
Publicado: (2022)

Virus-Vectored Ebola Vaccines
por: Dolzhikova, I.V., et al.
Publicado: (2017)

Ebola and Marburg virus vaccines
por: Reynolds, Pierce, et al.
Publicado: (2017)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
por: Kainulainen, Markus H., et al.
Publicado: (2023)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
por: Vianello, Eleonora, et al.
Publicado: (2022)

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas
por: Schwartz, David A.
Publicado: (2020)

Containing Ebola at the Source with Ring Vaccination
por: Merler, Stefano, et al.
Publicado: (2016)

Female sex workers in Kigali, Rwanda: a key population at risk of HIV, sexually transmitted infections, and unplanned pregnancy
por: Ingabire, Rosine, et al.
Publicado: (2019)

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea
por: Boum, Yap, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ocnqc73s17i61g0bm8bgp9le0q